Valuation: Akeso, Inc.

Capitalization 116B 126B 16.09B 13.81B 12.86B 11.97B 22.08B 1,386B 24.66B 155B 58.67B 650B 60.36B 59.11B 2,389B P/E ratio 2025 *
1,287x
P/E ratio 2026 * 129x
Enterprise value 116B 127B 16.12B 13.83B 12.89B 11.99B 22.13B 1,389B 24.71B 156B 58.78B 651B 60.48B 59.23B 2,393B EV / Sales 2025 *
32.9x
EV / Sales 2026 * 20.7x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.86%
1 week+24.29%
Current month+53.02%
1 month+48.50%
3 months+69.62%
6 months+137.87%
Current year+131.80%
More quotes
1 week 112.6
Extreme 112.6
142.8
1 month 89
Extreme 89
142.8
Current year 54
Extreme 54
142.8
1 year 38.8
Extreme 38.8
142.8
3 years 19.22
Extreme 19.22
142.8
5 years 11.5
Extreme 11.5
142.8
10 years 11.5
Extreme 11.5
142.8
More quotes
Manager TitleAgeSince
Corporate Officer/Principal 49 2019-11-15
Corporate Officer/Principal 56 2019-11-15
Chief Tech/Sci/R&D Officer 57 2019-11-15
Director TitleAgeSince
Chairman 58 2012-03-18
Director/Board Member 57 2019-11-15
Director/Board Member 56 2019-11-15
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.86%+24.29%+249.57%+515.75% 16.09B
+0.24%+2.39%+15.57%+35.09% 35.09B
+1.95%+7.06%+108.59%-18.67% 32.89B
-0.92%-2.54%+28.74%-33.21% 27.09B
-1.55%+4.46%+34.99%+333.64% 19.48B
-5.18%+4.80%+198.24%+2,239.29% 19.46B
+0.88%+7.13%+154.00%-62.61% 14.8B
-0.07%+3.01%-23.33%-44.07% 13.63B
-0.89%-0.87%+96.77%+103.62% 12.13B
+1.09%+14.29%+159.07% - 11.32B
Average -0.36%+6.29%+102.22%+340.98% 20.2B
Weighted average by Cap. -0.28%+5.32%+91.03%+303.24%
See all sector performances

Financials

2025 *2026 *
Net sales 3.52B 3.85B 491M 421M 392M 365M 674M 42.27B 752M 4.74B 1.79B 19.82B 1.84B 1.8B 72.85B 5.44B 5.95B 758M 650M 606M 564M 1.04B 65.27B 1.16B 7.32B 2.76B 30.6B 2.84B 2.78B 112B
Net income 87.64M 95.8M 12.21M 10.47M 9.76M 9.08M 16.75M 1.05B 18.71M 118M 44.5M 493M 45.79M 44.84M 1.81B 880M 962M 123M 105M 98.03M 91.21M 168M 10.56B 188M 1.18B 447M 4.95B 460M 450M 18.2B
Net Debt 221M 242M 30.78M 26.41M 24.61M 22.9M 42.24M 2.65B 47.17M 297M 112M 1.24B 115M 113M 4.57B -3.13B -3.42B -436M -374M -348M -324M -598M -37.53B -668M -4.21B -1.59B -17.59B -1.63B -1.6B -64.67B
More financial data * Estimated data
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,035
More about the company
Date Price Change Volume
25-07-18 140.70 $ +0.86% 10,315,560
25-07-17 139.50 $ +10.71% 16,822,560
25-07-16 126.00 $ +4.39% 12,011,770
25-07-15 120.70 $ +2.12% 10,442,910
25-07-14 118.20 $ +4.42% 9,761,890

Delayed Quote Hong Kong S.E., July 18, 2025 at 04:08 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
128.72CNY
Average target price
104.36CNY
Spread / Average Target
-18.93%
Consensus

Quarterly revenue - Rate of surprise